Catalog No.
YHD84801
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Cys915-His1173
Predicted molecular weight
32.12 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P29597
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Non-receptor tyrosine-protein kinase TYK2, TYK2
Case Report: Effectiveness of deucravacitinib in chronic recurrent multifocal osteomyelitis and concomitant psoriasis., PMID:40475785
Identification of novel drug targets through integrative PWAS of brain and plasma proteins with Ulcerative Colitis GWAS., PMID:40446056
Pharmacophore Modeling of Janus Kinase Inhibitors: Tools for Drug Discovery and Exposition Prediction., PMID:40430355
The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects., PMID:40424417
A triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors., PMID:40378946
Effects of naphthoquinone scaffold-derived compounds on head and neck squamous cell carcinoma based on network pharmacology and molecular docking., PMID:40371090
Pharmacological inhibition of tyrosine protein-kinase 2 reduces islet inflammation and delays type 1 diabetes onset in mice., PMID:40335415
Paradoxical Activation of Entheseal Myeloid Cells by JAK1 and TYK2 Inhibitors via IL10 Antagonism., PMID:40320905
Molecular characterization, expression, evolutionary analysis and molecular docking of the Janus activated kinase family members of largemouth bass (Micropterus salmoides)., PMID:40288622
Retraction Note: Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon., PMID:40253341
ART26.12, an FABP5 Inhibitor, Shows Efficacy in Preclinical Psoriasis Models., PMID:40210114
Identification of small molecule activators targeting TYK2 pseudokinase domain., PMID:40209917
Computational insights of deucravacitinib's selectivity for TYK2 pseudokinase vs. JAK kinase domain via molecular modeling studies., PMID:40200906
Malignant JAK-signaling: at the interface of inflammation and malignant transformation., PMID:40140631
Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulator., PMID:40127268
Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model., PMID:40116635
JAK inhibition and axial spondyloarthritis: new steps on the path to understanding pathophysiology., PMID:40103808
Modified expression of JAK-STAT pathway genes in an in vivo rheumatoid arthritis model: A preclinical study to explore genetic insights., PMID:40073707
A focused report on IFN-1 targeted therapies for lupus erythematosus., PMID:40047795
Topical TYK2 inhibitor ameliorates psoriasis-like dermatitis via the AKT-SP1-NGFR-AP1 pathway in keratinocytes., PMID:40038877
Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions., PMID:40025196
Therapeutic Advancements in Psoriasis and Psoriatic Arthritis., PMID:40004842
Increase Docking Score Screening Power by Simple Fusion With CNNscore., PMID:39981784
Synergistic role of gut-microbial L-ornithine in enhancing ustekinumab efficacy for Crohn's disease., PMID:39978335
Deciphering the role of TYK2 in tau phosphorylation and pathology., PMID:39934052
A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel., PMID:39913225
A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings., PMID:39906744
Acneiform Eruption Secondary to Deucravacitinib: A Case Series and Review of the Literature., PMID:39891469
Cross-trait GWAS in COVID-19 and systemic sclerosis reveals novel genes implicated in fibrotic and inflammation pathways., PMID:39878951
Anti-Inflammatory Effects of Cannabigerol In Vitro and In Vivo Are Mediated Through the JAK/STAT/NFκB Signaling Pathway., PMID:39851511
Tp53 determines the spatial dynamics of M1/M2 tumor-associated macrophages and M1-driven tumoricidal effects., PMID:39843434
TYK2 :p.Pro1104Ala Variant Protects Against Autoimmunity by Modulating Immune Cell Levels., PMID:39835539
Peficitinib suppresses diffuse-type tenosynovial giant cell tumor by targeting TYK2 and JAK/STAT signaling., PMID:39808223
Dual inhibition of TYK2 and PD-L1 boosts immune response in triple negative breast cancer., PMID:39774369
In Silico Screening of Phytochemicals as Potential Inhibitors of the JAK/STATs Pathway in Psoriasis., PMID:39772997
Molecular basis of JAK kinase regulation guiding therapeutic approaches: Evaluating the JAK3 pseudokinase domain as a drug target., PMID:39755448
Evaluation of Machine Learning/Molecular Mechanics End-State Corrections with Mechanical Embedding to Calculate Relative Protein-Ligand Binding Free Energies., PMID:39753520
Inhibiting Tyrosine Kinase 2 Ameliorates Antiphospholipid Syndrome Nephropathy., PMID:39742289
Fine-tuning SLE treatment: the potential of selective TYK2 inhibition., PMID:39740929
Association of tyrosine kinase 2 polymorphisms with susceptibility to microscopic polyangiitis in a Guangxi population., PMID:39726748
Modulation of IL-6 receptor/STAT3 downstream signaling in rheumatoid arthritis patients., PMID:39724808
Selective JAK1 inhibitors and the therapeutic applications thereof: a patent review (2016-2023)., PMID:39716925
SS18-SSX drives TYK2 expression to activate STAT3/Bcl2 axis, facilitating apoptosis evasion and advancing synovial sarcoma progression., PMID:39707021
Influence of head and neck cancer exosomes on macrophage polarization., PMID:39700664
Characterising a Novel Therapeutic Target for Psoriasis, TYK2, Using Functional Genomics., PMID:39684939
Tyrosine kinase 2 inhibitors: Synthesis and applications in the treatment of autoimmune diseases., PMID:39662285
Association study of the JAK/STAT signaling pathway with susceptibility to COVID-19 in moroccan patient and in-silico analysis of rare variants., PMID:39647533
A systematic review of the efficacy of TYK2 inhibitors in patients with dermatological disease., PMID:39641243
JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician., PMID:39629448
Kinase-Bench: Comprehensive Benchmarking Tools and Guidance for Achieving Selectivity in Kinase Drug Discovery., PMID:39623285
For research use only. Not for human or drug use.
